NCT06542796 Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma
| NCT ID | NCT06542796 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Condition | Hepatocellular Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-09-01 |
| Primary Completion | 2027-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2024-09-01 with a primary completion date of 2027-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Through a retrospective study of patients who underwent comprehensive treatment for hepatocellular carcinoma at the Second Affiliated Hospital of Zhejiang University, we explored the risk factors related to the sensitivity of comprehensive treatment. We used the PD-L1 expression level of patients before comprehensive treatment，characteristic morphology of tertiary lymphoid structures, as well as other parameters, are used to construct a liver cancer comprehensive treatment efficacy evaluation model. Using this liver cancer comprehensive treatment efficacy evaluation model, we conducted a randomized controlled trial on whether to receive comprehensive treatment for liver cancer patients to verify the accuracy and practical value of the model.
Eligibility Criteria
Inclusion Criteria: * Patients with advanced hepatocellular carcinoma Exclusion Criteria: * Have comorbidities of severe diabetes, heart failure, liver and/or kidney failure * Have a history of schizophrenia * Have a history of other malignant tumors or metastatic liver tumors discovered after surgery * Received anti-tumor drugs for other diseases * Special groups such as pregnant and lactating women.
Frequently Asked Questions
Who can join the NCT06542796 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Hepatocellular Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06542796 currently recruiting?
Yes, NCT06542796 is actively recruiting participants. Visit ClinicalTrials.gov or contact Second Affiliated Hospital, School of Medicine, Zhejiang University to inquire about joining.
Where is the NCT06542796 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT06542796 clinical trial?
NCT06542796 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.